Non-small cell lung carcinoma
Non-small cell lung carcinoma (NSCLC) is a type of lung cancer that is characterized by its non-small cells. It is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is further divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
Epidemiology[edit | edit source]
NSCLC is the most common type of lung cancer, accounting for about 85% of all cases. It is more common in men than in women, and the risk of developing NSCLC increases with age. The highest incidence of NSCLC is found in North America, Europe, and East Asia.
Causes[edit | edit source]
The primary cause of NSCLC is smoking, with approximately 85% of cases being attributed to tobacco use. Other risk factors include exposure to asbestos, radon, and certain other chemicals, as well as a family history of lung cancer.
Symptoms[edit | edit source]
The symptoms of NSCLC can vary widely and may include a persistent cough, chest pain, shortness of breath, and unexplained weight loss. In some cases, NSCLC may be discovered incidentally during a routine chest X-ray or CT scan.
Diagnosis[edit | edit source]
The diagnosis of NSCLC typically involves a combination of imaging studies, such as a chest X-ray or CT scan, and a biopsy to confirm the presence of cancer cells. Additional tests may be performed to determine the stage of the cancer and to guide treatment decisions.
Treatment[edit | edit source]
The treatment of NSCLC depends on the stage of the disease, the patient's overall health, and the specific subtype of NSCLC. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.
Prognosis[edit | edit source]
The prognosis for NSCLC varies widely depending on the stage of the disease at diagnosis. Early-stage NSCLC has a relatively good prognosis, with a 5-year survival rate of approximately 50%. However, the prognosis for advanced-stage NSCLC is generally poor, with a 5-year survival rate of less than 10%.
See also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
